Thermo Fisher Scientific Inc. $TMO Stock Bought by Fenimore Asset Management Inc

Fenimore Asset Management Inc boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 781.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 53,830 shares of the medical research company’s stock after purchasing an additional 47,720 shares during the period. Fenimore Asset Management Inc’s holdings in Thermo Fisher Scientific were worth $36,338,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. State Street Corp boosted its stake in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after acquiring an additional 229,630 shares during the last quarter. Corient Private Wealth LP purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $382,547,000. Bank of New York Mellon Corp bought a new position in Thermo Fisher Scientific in the 2nd quarter worth $1,974,561,000. Finally, Bank of America Corp DE purchased a new position in Thermo Fisher Scientific during the second quarter valued at $1,952,930,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $10.43 during trading hours on Thursday, hitting $651.63. The company’s stock had a trading volume of 2,585,462 shares, compared to its average volume of 2,253,558. The company has a market cap of $240.94 billion, a PE ratio of 35.05, a PEG ratio of 2.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The business has a 50 day moving average price of $624.23 and a two-hundred day moving average price of $539.29. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $694.33.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter last year, the company earned $4.28 EPS. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their price target for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Barclays lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $635.55.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.